Full Coverage
FDA approves X4 Pharmaceuticals' drug for ultra-rare WHIM syndrome
By jonathan saltzman
All coverage
Drug Licensed from Sanofi Becomes First FDA-Approved Therapy for Ultra-Rare Primary Immunodeficiency
By Frank Vinluan
Earnings call: X4 Pharmaceuticals reports Q1 2024 results and drug developments
By Natashya Angelica
X4 enters commercial fold with FDA approval of rare disease drug Xolremdi
By Fraiser Kansteiner
FDA Approves X4 Pharmaceuticals' Mavorixafor As First Therapy For Rare Immunodeficiency Disorder - X4 Pha
By Vandana Singh
XFOR: XOLREMDI™ Approved by FDA…
By David Bautz
FDA Approves First Targeted Treatment for WHIM Syndrome
By Tyler Patchen